{"id":"bnt162b2-mrna-covid-19-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Muscle pain"},{"rate":"null","effect":"Chills"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine uses a piece of the viral genome, called messenger RNA (mRNA), to instruct cells to produce a protein from the SARS-CoV-2 virus. This protein is then recognized by the immune system, which mounts a response to the perceived threat, providing immunity against future infections.","oneSentence":"BNT162b2 mRNA Covid-19 Vaccine works by instructing cells to produce a piece of the SARS-CoV-2 virus, prompting an immune response without causing the disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:20:07.887Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 disease caused by SARS-CoV-2 virus"}]},"trialDetails":[{"nctId":"NCT05212610","phase":"PHASE4","title":"Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-03-21","conditions":"COVID-19, Corona Virus Infection","enrollment":137},{"nctId":"NCT04368728","phase":"PHASE2, PHASE3","title":"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-04-29","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":46969},{"nctId":"NCT05265065","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-27","conditions":"COVID-19","enrollment":601},{"nctId":"NCT05283902","phase":"","title":"Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly","status":"COMPLETED","sponsor":"Federal University of Espirito Santo","startDate":"2022-03-19","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine-Preventable Diseases","enrollment":260},{"nctId":"NCT04649021","phase":"PHASE2","title":"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-12-04","conditions":"SARS-CoV-2","enrollment":960},{"nctId":"NCT05876377","phase":"","title":"Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-10-23","conditions":"SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome","enrollment":1},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT07280858","phase":"PHASE1, PHASE2","title":"A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-01-28","conditions":"Healthy Participants, Sarbecovirus","enrollment":368},{"nctId":"NCT07222384","phase":"PHASE3","title":"A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":"COVID-19, SARS-COV-2 Infection","enrollment":343},{"nctId":"NCT07390968","phase":"PHASE2","title":"Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-09-01","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":56},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT04760704","phase":"","title":"Covid-19 Vaccine Response in Elderly Subjects","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2021-02-18","conditions":"Covid19 Vaccine","enrollment":264},{"nctId":"NCT07300839","phase":"PHASE3","title":"A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-12-10","conditions":"COVID-19, SARS-COV-2 Infection","enrollment":25500},{"nctId":"NCT07069309","phase":"PHASE3","title":"A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2025-07-08","conditions":"COVID-19, SARS-COV-2 Infection","enrollment":760},{"nctId":"NCT04780659","phase":"PHASE4","title":"COVID-19 Vaccination of Immunodeficient Persons (COVAXID)","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2021-02-23","conditions":"Covid19","enrollment":539},{"nctId":"NCT06831786","phase":"EARLY_PHASE1","title":"Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2024-03-01","conditions":"COVID - 19","enrollment":36},{"nctId":"NCT06923137","phase":"","title":"A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-04-16","conditions":"COVID-19 SARS-CoV-2 Infection, COVID-19, COVID-19 Infection","enrollment":1},{"nctId":"NCT05032976","phase":"","title":"Korea Comirnaty Post-marketing Surveillance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-18","conditions":"COVID-19, Vaccines, Adverse Effects","enrollment":12000},{"nctId":"NCT04955626","phase":"PHASE3","title":"To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-07-01","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":16372},{"nctId":"NCT06742281","phase":"PHASE2","title":"A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"CyanVac LLC","startDate":"2024-12-05","conditions":"COVID-19","enrollment":432},{"nctId":"NCT06672055","phase":"PHASE2","title":"A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaxart","startDate":"2024-10-08","conditions":"SARS-CoV2, COVID-19","enrollment":10400},{"nctId":"NCT05289037","phase":"PHASE2","title":"COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-03-30","conditions":"COVID-19","enrollment":1270},{"nctId":"NCT06237049","phase":"PHASE2","title":"A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-01-31","conditions":"Influenza, Human, SARS-CoV-2 Infection, COVID-19","enrollment":644},{"nctId":"NCT06452654","phase":"PHASE4","title":"Anti-viral Action Against Type 1 Diabetes Autoimmunity","status":"RECRUITING","sponsor":"Technical University of Munich","startDate":"2024-05-08","conditions":"Diabetes Mellitus, Type 1","enrollment":2252},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT05000216","phase":"PHASE2","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-13","conditions":"Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris","enrollment":258},{"nctId":"NCT05571735","phase":"","title":"Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-04-15","conditions":"Covid-19 Pandemics, Tuberculosis","enrollment":133},{"nctId":"NCT04761822","phase":"PHASE2","title":"COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-07","conditions":"SARS-CoV Infection, COVID-19, Allergic Reaction","enrollment":746},{"nctId":"NCT04932863","phase":"","title":"BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment","status":"COMPLETED","sponsor":"Ente Ospedaliero Ospedali Galliera","startDate":"2021-03-15","conditions":"Neoplasms, Cancer, Treatment-Related","enrollment":300},{"nctId":"NCT04969263","phase":"PHASE2","title":"COVID-19 Protection After Transplant Pilot Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-10","conditions":"Kidney Transplant Recipients","enrollment":81},{"nctId":"NCT04848584","phase":"","title":"Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-15","conditions":"COVID-19","enrollment":1},{"nctId":"NCT06743334","phase":"","title":"Secondary Databased Post-marketing Surveillance Study of BNT162b2","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-04-23","conditions":"COVID-19, SARS-CoV-2","enrollment":1},{"nctId":"NCT05321407","phase":"","title":"COVID-19 Vaccine Responses in PIDD Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2021-09-30","conditions":"X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency","enrollment":100},{"nctId":"NCT05525208","phase":"PHASE2","title":"Booster Study of COVID-19 Protein Subunit Recombinant Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-09-01","conditions":"COVID-19","enrollment":696},{"nctId":"NCT05621239","phase":"","title":"A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-03-15","conditions":"COVID-19","enrollment":260},{"nctId":"NCT05160766","phase":"PHASE2","title":"Assessing Immune Response of Different COVID-19 Vaccines in Older Adults","status":"COMPLETED","sponsor":"Oliver Cornely, MD","startDate":"2021-11-08","conditions":"Prevention of COVID-19","enrollment":323},{"nctId":"NCT04889209","phase":"PHASE1, PHASE2","title":"Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-28","conditions":"COVID-19","enrollment":867},{"nctId":"NCT06919796","phase":"PHASE2","title":"mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes","status":"NOT_YET_RECRUITING","sponsor":"PharmaJet, Inc.","startDate":"2025-05-01","conditions":"Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2","enrollment":40},{"nctId":"NCT05997290","phase":"PHASE2, PHASE3","title":"A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-08-10","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":1051},{"nctId":"NCT04894435","phase":"PHASE2","title":"Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2021-05-20","conditions":"COVID-19","enrollment":669},{"nctId":"NCT05329220","phase":"PHASE3","title":"ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2022-08-30","conditions":"COVID-19 Disease","enrollment":4205},{"nctId":"NCT05022329","phase":"PHASE2, PHASE3","title":"COVID-19 Vaccine Boosters in Patients With CKD","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-09-30","conditions":"Chronic Kidney Diseases, COVID-19","enrollment":273},{"nctId":"NCT05354024","phase":"PHASE2, PHASE3","title":"Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-02-28","conditions":"Coronavirus Infections, Healthy","enrollment":4400},{"nctId":"NCT05886777","phase":"PHASE2","title":"A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-05","conditions":"Healthy Participants","enrollment":1142},{"nctId":"NCT05228730","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).","status":"TERMINATED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":13},{"nctId":"NCT05047718","phase":"PHASE4","title":"Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2021-10-05","conditions":"Covid19","enrollment":54},{"nctId":"NCT05599555","phase":"","title":"Community-based Sero-epidemiological Study of COVID-19","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2022-04-28","conditions":"COVID-19","enrollment":9600},{"nctId":"NCT04754594","phase":"PHASE2, PHASE3","title":"To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-02-16","conditions":"SARS-CoV-2 Infection, COVID-19, Maternal Immunization","enrollment":726},{"nctId":"NCT04815031","phase":"","title":"Drug Use Investigation of COMIRNATY Intramuscular Injection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-03-20","conditions":"COVID-19","enrollment":14570},{"nctId":"NCT05004181","phase":"PHASE2","title":"Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-08-25","conditions":"SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease","enrollment":1380},{"nctId":"NCT05697705","phase":"","title":"Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-22","conditions":"COVID-19","enrollment":188814085},{"nctId":"NCT05993325","phase":"PHASE3","title":"Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cellid Co., Ltd.","startDate":"2023-11-27","conditions":"COVID-19, Vaccines","enrollment":4000},{"nctId":"NCT05142319","phase":"PHASE4","title":"Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2021-10-12","conditions":"COVID-19","enrollment":326},{"nctId":"NCT04895982","phase":"PHASE2","title":"Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-10-15","conditions":"SARS-CoV-2 Infection, COVID19","enrollment":124},{"nctId":"NCT06597370","phase":"","title":"Immunogenicity Induced by COVID-19 Vaccines in Mexican Population","status":"COMPLETED","sponsor":"National Polytechnic Institute, Mexico","startDate":"2021-09-01","conditions":"COVID-19 Vaccine","enrollment":80},{"nctId":"NCT05858450","phase":"","title":"This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-05-05","conditions":"Influenza, Human, COVID-19","enrollment":3442996},{"nctId":"NCT04922944","phase":"","title":"Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients","status":"COMPLETED","sponsor":"Huntington Memorial Hospital","startDate":"2021-03-08","conditions":"Covid19, Vaccine Reaction","enrollment":167},{"nctId":"NCT04949490","phase":"PHASE2","title":"A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-07-26","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":137},{"nctId":"NCT06587503","phase":"PHASE4","title":"Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses","status":"NOT_YET_RECRUITING","sponsor":"University of Birmingham","startDate":"2024-10","conditions":"Ebola Virus Disease, COVID-19","enrollment":72},{"nctId":"NCT05765578","phase":"","title":"An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-08","conditions":"COVID-19","enrollment":1713},{"nctId":"NCT05016622","phase":"PHASE2","title":"Booster Dose Trial","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2021-08-10","conditions":"Cancer","enrollment":106},{"nctId":"NCT05515042","phase":"PHASE2","title":"Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2022-07-25","conditions":"COVID-19","enrollment":694},{"nctId":"NCT04380701","phase":"PHASE1, PHASE2","title":"A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-04-23","conditions":"Infections, Respiratory, Virus Diseases, Infection Viral","enrollment":512},{"nctId":"NCT04969601","phase":"PHASE1, PHASE2","title":"Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-29","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":76},{"nctId":"NCT04880447","phase":"","title":"Special Investigation of COMIRNATY in the Population With Underlying Diseases","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-26","conditions":"COVID-19","enrollment":1075},{"nctId":"NCT04792567","phase":"PHASE4","title":"Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-04-19","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":41},{"nctId":"NCT05310084","phase":"PHASE3","title":"Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-04-20","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":1134},{"nctId":"NCT05047640","phase":"PHASE3","title":"COVID-19 3rd Dose Vaccine in Transplant Patients","status":"TERMINATED","sponsor":"Giselle Guerra","startDate":"2021-09-14","conditions":"Covid19","enrollment":58},{"nctId":"NCT05977127","phase":"PHASE2","title":"Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2023-09-26","conditions":"Vaccination; Infection, COVID-19","enrollment":48},{"nctId":"NCT04969250","phase":"PHASE4","title":"Vaccination for Recovered Inpatients With COVID-19 (VATICO)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-25","conditions":"Covid19","enrollment":66},{"nctId":"NCT05970887","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines","status":"COMPLETED","sponsor":"Catholic Kwandong University","startDate":"2022-10-12","conditions":"Immune Response, Safety","enrollment":154},{"nctId":"NCT05406908","phase":"PHASE4","title":"Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2022-06-15","conditions":"Bullous Dermatoses, Psoriasis, COVID-19 Vaccines","enrollment":109},{"nctId":"NCT05387317","phase":"PHASE3","title":"Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-04","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05781191","phase":"","title":"Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-11-13","conditions":"Influenza, COVID-19","enrollment":8231},{"nctId":"NCT05543356","phase":"PHASE3","title":"COVID-19 Fourth Dose Study in Australia","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04898946","phase":"","title":"Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong","status":"COMPLETED","sponsor":"Hong Kong Sanatorium & Hospital","startDate":"2021-03-07","conditions":"Covid-19 Vaccine","enrollment":480},{"nctId":"NCT05020145","phase":"","title":"COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-25","conditions":"Immunocompromised, Immunosuppressed, Covid-19","enrollment":1277747},{"nctId":"NCT05239975","phase":"PHASE2","title":"A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine","status":"WITHDRAWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-04-25","conditions":"COVID-19, SARS-CoV2 Infection","enrollment":""},{"nctId":"NCT05343871","phase":"PHASE4","title":"Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2022-07-05","conditions":"COVID-19","enrollment":2354},{"nctId":"NCT04832932","phase":"","title":"The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes","status":"UNKNOWN","sponsor":"Mebo Research, Inc.","startDate":"2021-01-05","conditions":"COVID-19 Vaccines","enrollment":2000},{"nctId":"NCT04805125","phase":"PHASE3","title":"Immunocompromised Swiss Cohorts Based Trial Platform","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-19","conditions":"Immunocompromised Patients","enrollment":610},{"nctId":"NCT05075538","phase":"PHASE4","title":"COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2021-12-01","conditions":"Cancer","enrollment":152},{"nctId":"NCT04800133","phase":"PHASE2","title":"Covid-19 Vaccination in Adolescents and Children","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-05-08","conditions":"Covid19","enrollment":1018},{"nctId":"NCT06189040","phase":"PHASE4","title":"Immunogenicity After COVID-19 Vaccines in Adapted Schedules","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2021-05-26","conditions":"Coronavirus Disease 2019, COVID-19","enrollment":580},{"nctId":"NCT05230953","phase":"PHASE3","title":"Fourth COVID-19 Vaccine Dose- mRNA1273","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2022-01-05","conditions":"COVID-19 Pandemic","enrollment":1000},{"nctId":"NCT05231005","phase":"PHASE4","title":"Fourth BNT162b2 COVID-19 Vaccine Dose","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2021-12-27","conditions":"COVID-19 Pandemic","enrollment":1000},{"nctId":"NCT04816643","phase":"PHASE2, PHASE3","title":"A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-03-24","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":11837},{"nctId":"NCT04824638","phase":"PHASE2","title":"BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-03-08","conditions":"Healthy, Immunization; Infection","enrollment":267},{"nctId":"NCT05057182","phase":"PHASE4","title":"Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-10-18","conditions":"COVID 19 Vaccine","enrollment":300},{"nctId":"NCT05057169","phase":"PHASE4","title":"Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-11-18","conditions":"COVID-19 Vaccination","enrollment":400},{"nctId":"NCT05052307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2021-11-03","conditions":"Covid19","enrollment":4574},{"nctId":"NCT05403307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2022-06-08","conditions":"COVID-19","enrollment":757},{"nctId":"NCT04977479","phase":"PHASE2","title":"The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-08","conditions":"Systemic Allergic Reaction","enrollment":20},{"nctId":"NCT05788185","phase":"PHASE1, PHASE2","title":"Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals","status":"TERMINATED","sponsor":"RVAC Medicines (US), Inc.","startDate":"2023-03-22","conditions":"Infectious Disease, COVID-19","enrollment":24},{"nctId":"NCT04775069","phase":"PHASE4","title":"Antibody Response to COVID-19 Vaccines in Liver Disease Patients","status":"COMPLETED","sponsor":"Humanity & Health Medical Group Limited","startDate":"2021-05-21","conditions":"Chronic Liver Disease","enrollment":232},{"nctId":"NCT04826770","phase":"","title":"Adaptive Immune Response to COVID-19 Vaccination","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2021-01-06","conditions":"SARS-CoV-2 Vaccination","enrollment":70},{"nctId":"NCT04523571","phase":"PHASE1","title":"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-07-28","conditions":"SARS-CoV-2","enrollment":144},{"nctId":"NCT05517642","phase":"PHASE3","title":"IH Convidecia as Second Booster Dose Against Breakthrough Infections","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2022-09-20","conditions":"COVID-19","enrollment":540},{"nctId":"NCT05602961","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster","status":"WITHDRAWN","sponsor":"GreenLight Biosciences, Inc.","startDate":"2023-02-21","conditions":"COVID-19","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":421,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BNT162b2 mRNA Covid-19 Vaccine","genericName":"BNT162b2 mRNA Covid-19 Vaccine","companyName":"Ente Ospedaliero Ospedali Galliera","companyId":"ente-ospedaliero-ospedali-galliera","modality":"Biologic","firstApprovalDate":"","aiSummary":"BNT162b2 mRNA Covid-19 Vaccine works by instructing cells to produce a piece of the SARS-CoV-2 virus, prompting an immune response without causing the disease. Used for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}